Clinical trials located in

Székesfehérvár

Székesfehérvár city is located in Hungary. Currently, 20 clinical trials are being conducted in this city.

Székesfehérvár, located in central Hungary, is a city steeped in history. Once the coronation city of Hungarian kings, it boasts a rich heritage dating back to the Roman era. The city was a significant royal and religious center during the Middle Ages, with over 40 kings crowned and 15 buried here. Its architecture reflects a blend of styles, from Romanesque to Gothic. Notable landmarks include the ruins of the Royal Basilica, destroyed during the Ottoman era, and the Bory Castle, a 20th-century fortress built by a single man. Székesfehérvár also played a pivotal role in Hungary’s industrial growth in the 20th century.

  • CT-EU-00117206

    Study on Secukinumab for Rotator Cuff Tendinopathy

    This here clinical trial is aimin’ to see if a new medicine called secukinumab can help folks with moderate to severe rotator cuff tendinopathy, which is a painful condition affectin’ the shoulder. The study will compare secukinumab to a placebo, which is like a fake medicine with no active ingredients.

    Now, if you join this trial, you’ll be given either secukinumab or the placebo by injection under the skin every week for the first month, and then once a month after that for another couple of months. The doctors will be keepin’ a close eye on your shoulder symptoms like pain, weakness, stiffness, and any mechanical issues you might be havin’.

    The main thing they’ll be lookin’ at is how much your physical shoulder symptoms improve after 16 weeks of treatment with secukinumab compared to the placebo. They’ll be usin’ a special questionnaire called the Western Ontario Rotator Cuff Index to measure them symptoms.

    Now, durin’ the trial, you’ll need to keep takin’ any anti-inflammatory medicines you’re already on, and keep up with your physical therapy exercises too. But you won’t be allowed to get no steroid injections or increase your medicine doses without the doctors’ say-so.

    After the 16 weeks of treatment, there’ll be another 8 weeks where the doctors will check if the effects of the medicine are lastin’. So in total, you’d be in the study for around 6 months if you join up.

    DenmarkGreeceHungaryItalyPolandSpain
  • A study comparing upadacitinib versus adalimumab in the treatment of rheumatoid arthritis

    This clinical trial is studying a new medication called upadacitinib for treating moderate to severe rheumatoid arthritis. Rheumatoid arthritis is a chronic condition that causes pain, stiffness, swelling, and loss of joint function. The study will compare upadacitinib, which is taken as an oral tablet once daily, to adalimumab (brand name Humira), which is an injection given under the skin every other week.

    The main goal is to see how effective upadacitinib is at reducing disease activity compared to adalimumab. The study will measure the percentage of participants who achieve a certain level of low disease activity based on a score called the DAS28-CRP, which looks at tender and swollen joints, overall disease activity, and inflammation levels.

    This is a double-blind study, meaning neither the participants nor the study doctors will know which treatment each participant is receiving. Participants will attend regular visits at a hospital or clinic for medical assessments, checking for side effects, and completing questionnaires. There may be a higher treatment burden compared to standard care. The study is designed to assess the safety and effectiveness of upadacitinib compared to adalimumab in treating moderate to severe rheumatoid arthritis.

    BelgiumBulgariaFranceGermanyGreeceHungaryItalyPortugalRomaniaSpainUnited Kingdom
  • Long-term safety study of efgartigimod in the treatment of primary Sjögren’s syndrome

    The study focuses on examining the medication efgartigimod and its potential to assist adults with Primary Sjögren’s Syndrome (pSS). Participants who have taken part in previous efgartigimod studies may qualify for this extension study. The primary aim is to assess the long-term safety of efgartigimod for individuals with pSS.

    During the 48-week duration of the study, participants will receive efgartigimod treatment. It’s important to understand that individuals from both the active and placebo groups of previous studies can participate, but they will not be informed of their previous group assignment. The researchers will closely monitor any side effects, including serious ones, as well as any changes in participants’ laboratory test results or vital signs throughout the study.

    This study offers an opportunity to further investigate the potential benefits of efgartigimod in managing pSS, particularly in reducing IgG autoantibodies, which are thought to contribute to the disease. Participation in the study could provide valuable insights into the long-term safety of this treatment.

    BelgiumHungaryPoland
  • Studying rilzabrutinib for chronic immune thrombocytopenia

    The research is underway to evaluate the efficacy and safety of a medication called rilzabrutinib in adults and teenagers with Immune Thrombocytopenia (ITP), a chronic blood condition characterized by a low platelet count. Participants will receive either the medication or a placebo twice daily over a period of about a year and a half. Platelet levels, overall health, and quality of life will be measured before and during the study to gather comprehensive data.

    AustriaFranceGermanyHungaryItalyNetherlandsNorwayPolandSpainUnited Kingdom
  • A comprehensive evaluation of retatrutide in obesity and associated comorbidities

    This study evaluates the effectiveness and safety of a new drug, retatrutide, in individuals with obesity or overweight, including those with knee osteoarthritis or obstructive sleep apnea. Lasting about 89 weeks, the trial involves randomized assignment of participants to either receive retatrutide or a placebo. The main goals are to observe changes in body weight, knee pain in osteoarthritis, and sleep apnea severity. The study also examines various secondary outcomes like changes in BMI, waist circumference, and blood pressure. The trial aims to provide new insights into weight management and associated health conditions, offering hope for improved treatments.

    HungaryPolandRomaniaSpainUnited Kingdom
  • Evaluating datopotamab deruxtecan & pembrolizumab for advanced lung cancer

    This study compares two treatments for people with a type of lung cancer called ‘non-small cell lung cancer’ that has spread to other parts of the body. It tests whether combining a drug called datopotamab deruxtecan (Dato-DXd) with pembrolizumab works better than using pembrolizumab alone. Aimed at patients with non-small cell lung cancer (NSCLC) who haven’t had previous systemic therapy, it’s especially for those with high PD-L1 tumor expression.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Comparison of drug combinations in the treatment of advanced lung cancer

    This trial studies a first-line treatment involving Dato-DXd plus pembrolizumab compared to pembrolizumab alone in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations. The goal is to evaluate the effectiveness and safety of this combined strategy. Target volunteers must not have received any treatments for their advanced or metastatic NSCLC. Participation includes receiving either the combined treatment or pembrolizumab alone. Regular health checks will monitor if any changes or adverse events occur during the trial.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Examining new drug combo vs. standard treatment with pembrolizumab for advanced lung cancer

    This trial is examining if a combination of two medications, Dato-DXd and pembrolizumab, could be superior to using pembrolizumab alone in treating a type of lung cancer known as metastatic non-small cell lung cancer (NSCLC). Participants will include those who have advanced or spread NSCLC and haven’t had systemic treatment for it. The team will be comparing whether the combination treatment can help patients live longer or keep the cancer from growing for a longer period. One group of participants will get pembrolizumab on its own, while another will get both Dato-DXd and pembrolizumab. An important part of the study will assess how the treatment affects the patient’s symptoms and quality of life.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Secukinumab study for maintaining remission in axial spondyloarthritis

    The aim of this study is to see if a drug called Secukinumab can maintain remission in people with non-radiographic axial spondyloarthritis (a type of spondylitis). Remission means that there is no or very little disease in the body. To determine whether a person is in remission, we use a special scoring system that looks at various symptoms of arthritis and a blood test for a protein associated with inflammation (C-reactive protein, or CRP). The aim of the study is to see whether people who stop taking Secukinumab will experience an exacerbation (worsening of the disease) and how long it takes for this to happen. The study will last just over two years.

    BelgiumCzechiaFranceGermanyHungaryItalyNetherlandsPolandRomania
  • Continued study of ozanimod for severe Crohn’s Disease

    This research is about an extended study on the use of an oral medication named Ozanimod for people suffering from Crohn’s disease. Crohn’s disease can make the stomach and intestines really uncomfortable, causing swellings and pain. The main aim of this study is to check if this medicine, Ozanimod, is safe for intake and how effective it is in easing these uncomfortable feelings in the stomach. The researchers will rate patients’ illnesses using the Crohn’s Disease Activity Index (a measurement tool).

    BelgiumBulgariaCzechiaFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Testing navitoclax and ruxolitinib effective on myelofibrosis patients

    This study is trying to find out if the combination of two drugs called Navitoclax and Ruxolitinib can help people with a type of blood cancer called Myelofibrosis. Around 330 adults, who have myelofibrosis that hasn’t responded to previous treatments, will get either the new drug combination or the current best treatment for their disease. Doctors will measure whether the new combination is more effective by checking how much the size of participants’ spleens have changed during the study with scans, measuring fatigue levels and checking how well their bone marrow works.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyPolandSpainSwedenUnited Kingdom
  • Studying ozanimod as ongoing treatment for Severe Crohn’s Disease

    This trial is to test a medication called Ozanimod on people who have a serious type of Crohn’s Disease. Crohn’s Disease can make the stomach hurt a lot and sometimes makes difficulty eating.  The researchers want to see if the medication helps to calm the disease, so patients feel better. Some patients will get the Ozanimod and others will get a placebo.  The researchers use  ‘Crohn’s Disease Activity Index’ to see how the disease is doing.

    BelgiumBulgariaCzechiaFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Understanding new medicine in moderate to severe ulcerative colitis or Crohn’s disease

    This is a study about a medicine called TEV-48574, used to treat serious bowel diseases called ulcerative colitis and Crohn’s disease. The main purpose of this study is to see how well the medicine works and how much of it should be given to patients, specifically, every 4 weeks. The study aims to test two different doses of TEV-48574 while assessing its safety and the ease with which patients can manage it. Additionally, the research aims to analyze the long-term reactions of the body to the medication. Each participant will be observed for up to 66 weeks, and the entire study is expected to span approximately 37 months. The success of the treatment will be gauged through various tests, including the Mayo score, which considers symptoms such as rectal bleeding, stool frequency, and inflammation within the gut.

    AustriaBelgiumBulgariaCzechiaFranceHungaryItalyPolandSlovakiaSpain
  • Studying retatrutide for treating obesity and heart disease

    This research study is about a medicine called Retatrutide (also known as LY3437943), which will be tested on people who have obesity and heart disease. The way this study will work is that some people will be given Retatrutide once a week, while others will be given a placebo, which doesn’t have any medicine in it. By doing this, the researchers can see if Retatrutide helps to improve health and if it is safe to use. The study will run for just over two years. AUC is a way for the study to measure the effect of Retatrutide on your body.

    HungaryPolandSlovakiaSpain
  • Long-term safety & efficacy study for Ianalumab in Sjogrens syndrome

    This study is testing a drug called ianalumab to see if it can help people with Sjogren’s syndrome. Participants will receive the drug once a month or once every three months. The study will last approximately five years. It involves taking the drug for three years and then being followed by researchers for another two years. Doctors are interested in whether the drug will work for a long time and whether it will be safe. What is important is that the study participants will be patients who have already completed the previous trial. If a patient received placebo treatment in the previous study, they will now receive the real drug once a month or once every three months. The most significant thing is to understand how this drug helps Sjogren’s syndrome eventually.

    AustriaCzechiaFranceGermanyHungaryPolandPortugalSlovakiaSpain
  • Study on anifrolumab effectiveness in patients with systemic lupus erythematosus

    This clinical trial is a Phase 3, interventional study focused on evaluating the safety and effectiveness of subcutaneous anifrolumab. Targeting adults aged 18 to 70 with moderately to severely active systemic lupus erythematosus (SLE) who are currently on standard treatments, the study involves about 360 participants. Participants receive either anifrolumab or a placebo once a week, with the primary outcomes assessed at Week 52.

    BulgariaGermanyHungaryPolandSpainUnited Kingdom
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom

See more clinical trials in other cities in Hungary:

.